mexiletine has been researched along with Pain in 46 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effects of mexiletine for symptoms and signs of myotonia in patients with NDMs." | 9.16 | Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. ( Barohn, RJ; Bundy, BN; Ciafaloni, E; Griggs, RC; Hanna, MG; Herbelin, L; Matthews, E; Meola, G; Rayan, DR; Salajegheh, MK; Sansone, VA; Statland, JM; Trivedi, JR; Venance, SL; Wang, Y, 2012) |
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 9.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "Although mexiletine, an antiarrhythmic with local anesthetic properties, has been reported to relieve discomfort in diabetic neuropathy, its usefulness in the treatment of HIV-related painful peripheral neuropathy (PPN) has not been determined." | 9.08 | Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. ( Burton, S; Deresinski, SC; Kemper, CA; Kent, G, 1998) |
| "A total of 216 insulin-treated diabetes patients with painful diabetic neuropathy were randomly allocated to three dosages of mexiletine or placebo." | 9.08 | Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. ( Lins, PE; Ljunggren, JG; Oskarsson, P, 1997) |
| "Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy." | 9.08 | A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. ( Clifford, DB; Cohen, B; Dal Pan, GJ; Ellis, RJ; Hall, CD; Kieburtz, K; Marra, CM; Max, MB; McKendall, R; Simpson, D; Singer, E; Tucker, T; Yiannoutsos, C, 1998) |
| "Lidocaine is a use-dependent sodium channel blocker that produces analgesia when administered intravenously to patients with neuropathic pain." | 8.84 | Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy. ( Carroll, I, 2007) |
| " Mexiletine, an orally available Na(+)-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy." | 7.76 | Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. ( Egashira, N; Hirakawa, S; Ikesue, H; Kawashiri, T; Oishi, R; Yano, T, 2010) |
| "The influence of mexiletine hydrochloride on herpes-related pain responses was examined using mice infected with herpes virus." | 7.72 | Attenuating effect of mexiletine hydrochloride on herpetic pain in mice infected with herpes simplex virus. ( Asano, K; Hisamitsu, T; Sameshima, T; Shirasawa, H, 2003) |
| "Dercum's disease (adiposis dolorosa) is associated with very painful subcutaneous fatty deposits normally localized to the lower extremities in which pain treatment is usually unsuccessful." | 6.66 | Dercum's disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine. ( Kastrup, J; Petersen, P, 1987) |
| "Physicians caring for patients with CSPN should consider mexiletine to address pain and fatigue, although nortriptyline and duloxetine are better medications to trial first since they are better tolerated." | 5.51 | A secondary analysis of PAIN-CONTRoLS: Pain's impact on sleep, fatigue, and activities of daily living. ( Barohn, RJ; Bhai, SF; Brown, A; Gajewski, B; Kimminau, KS; Pasnoor, M; Waitman, LR, 2022) |
| "Furthermore, fenvalerate-induced thermal allodynia and hyperalgesia were inhibited by the pretreatment with calphostin C." | 5.31 | Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate. ( Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2001) |
| "Mexiletine was generally well tolerated with only two patients experiencing transient nausea and dizziness." | 5.28 | Mexiletine for thalamic pain syndrome. ( Awerbuch, GI; Sandyk, R, 1990) |
| "To determine the effects of mexiletine for symptoms and signs of myotonia in patients with NDMs." | 5.16 | Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. ( Barohn, RJ; Bundy, BN; Ciafaloni, E; Griggs, RC; Hanna, MG; Herbelin, L; Matthews, E; Meola, G; Rayan, DR; Salajegheh, MK; Sansone, VA; Statland, JM; Trivedi, JR; Venance, SL; Wang, Y, 2012) |
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 5.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "A total of 216 insulin-treated diabetes patients with painful diabetic neuropathy were randomly allocated to three dosages of mexiletine or placebo." | 5.08 | Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. ( Lins, PE; Ljunggren, JG; Oskarsson, P, 1997) |
| "Although mexiletine, an antiarrhythmic with local anesthetic properties, has been reported to relieve discomfort in diabetic neuropathy, its usefulness in the treatment of HIV-related painful peripheral neuropathy (PPN) has not been determined." | 5.08 | Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. ( Burton, S; Deresinski, SC; Kemper, CA; Kent, G, 1998) |
| "Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy." | 5.08 | A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. ( Clifford, DB; Cohen, B; Dal Pan, GJ; Ellis, RJ; Hall, CD; Kieburtz, K; Marra, CM; Max, MB; McKendall, R; Simpson, D; Singer, E; Tucker, T; Yiannoutsos, C, 1998) |
| "To prove the efficacy of mexiletine in painful diabetic neuropathy." | 5.07 | Mexiletine in the treatment of diabetic neuropathy. ( Federlin, K; Meyer, UE; Schumacher, HE; Stracke, H, 1992) |
| "Lidocaine is a use-dependent sodium channel blocker that produces analgesia when administered intravenously to patients with neuropathic pain." | 4.84 | Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy. ( Carroll, I, 2007) |
| "Lidocaine and oral analogs were safe drugs in controlled clinical trials for neuropathic pain, were better than placebo, and were as effective as other analgesics." | 4.82 | Systemic administration of local anesthetic agents to relieve neuropathic pain. ( Carr, DB; Challapalli, V; Lau, J; McNicol, ED; Tremont-Lukats, IW, 2005) |
| " Mexiletine, an orally available Na(+)-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy." | 3.76 | Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. ( Egashira, N; Hirakawa, S; Ikesue, H; Kawashiri, T; Oishi, R; Yano, T, 2010) |
| " In this study, we investigated the effects of M58373 on substance P release from sensory neurons in vitro and pain behaviors/responses in rats, compared with mexiletine." | 3.73 | Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. ( Akada, Y; Amano, K; Fukudome, Y; Itoh, M; Ogawa, S; Yamamoto, I; Yamasaki, F, 2006) |
| "The influence of mexiletine hydrochloride on herpes-related pain responses was examined using mice infected with herpes virus." | 3.72 | Attenuating effect of mexiletine hydrochloride on herpetic pain in mice infected with herpes simplex virus. ( Asano, K; Hisamitsu, T; Sameshima, T; Shirasawa, H, 2003) |
| "Mexiletine is widely used for the treatment of neuropathic pain although its site(s) of action remain unclear." | 3.70 | A novel spinal action of mexiletine in spinal somatosensory transmission of nerve injured rats. ( Chapman, V; Dickenson, AH; Ng, J, 1998) |
| "Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i." | 3.69 | The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997) |
| "We examined the effect of mexiletine on the threshold for pain perception as determined by the application of mechanical noxious stimuli (tail-pinch) in diabetic mice." | 3.68 | Antinociceptive effect of mexiletine in diabetic mice. ( Aoki, T; Hitosugi, H; Kamei, J; Kasuya, Y; Kawashima, N; Ohhashi, Y, 1992) |
| "Dercum's disease (adiposis dolorosa) is associated with very painful subcutaneous fatty deposits normally localized to the lower extremities in which pain treatment is usually unsuccessful." | 2.66 | Dercum's disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine. ( Kastrup, J; Petersen, P, 1987) |
| "neuropathic pain) is not very satisfactorily managed." | 2.44 | [Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008) |
| " Compound 4 had good efficacy (52% and 41% reversal of allodynia at 2 and 4h post-dose, respectively) in the Chung rat spinal nerve ligation (SNL) model of neuropathic pain when dosed orally at 10mg/kg." | 1.35 | Imidazopyridines: a novel class of hNav1.7 channel blockers. ( Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Martin, WJ; McGowan, E; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS, 2008) |
| "Furthermore, fenvalerate-induced thermal allodynia and hyperalgesia were inhibited by the pretreatment with calphostin C." | 1.31 | Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate. ( Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2001) |
| "Acyclovir treatment healed all skin lesions by day 15 after inoculation." | 1.31 | Effects of analgesics on delayed postherpetic pain in mice. ( Andoh, T; Kuraishi, Y; Nojima, H; Sasaki, A; Shiraki, K; Takasaki, I, 2002) |
| "Pretreatment with mexiletine (5-30 mg/kg i." | 1.30 | Comparable dose-dependent inhibition of AP-7 sensitive strychnine-induced allodynia and paw pinch-induced nociception by mexiletine in the rat. ( Hodge, E; Khandwala, H; Loomis, CW, 1997) |
| "Dercum's disease (adiposis dolorosa) is a rare condition characterized by progressively painful fatty deposits, usually, in menopausal women with obesity, asthenia and mental phenomena." | 1.30 | Dercum's disease (adiposis dolorosa). ( O'Flynn, P; Reece, PH; Wyatt, M, 1999) |
| "Mexiletine was generally well tolerated with only two patients experiencing transient nausea and dizziness." | 1.28 | Mexiletine for thalamic pain syndrome. ( Awerbuch, GI; Sandyk, R, 1990) |
| "SUN 1165 had no effect on clonic convulsions induced by pentetrazol and pictrotoxin in mice, while both mexiletine and lidocaine prolonged the duration of clonic convulsions." | 1.27 | General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system. ( Hashimoto, Y; Hatta, M; Hattori, Y; Hirotsu, I; Ishihara, T; Kihara, T; Kitakaze, Y; Miyata, T; Nakamura, S; Takahama, K, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.35) | 18.7374 |
| 1990's | 23 (50.00) | 18.2507 |
| 2000's | 16 (34.78) | 29.6817 |
| 2010's | 4 (8.70) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Jarvis, MF | 1 |
| Honore, P | 1 |
| Shieh, CC | 1 |
| Chapman, M | 1 |
| Joshi, S | 1 |
| Zhang, XF | 1 |
| Kort, M | 1 |
| Carroll, W | 1 |
| Marron, B | 1 |
| Atkinson, R | 1 |
| Thomas, J | 1 |
| Liu, D | 2 |
| Krambis, M | 1 |
| Liu, Y | 1 |
| McGaraughty, S | 1 |
| Chu, K | 1 |
| Roeloffs, R | 1 |
| Zhong, C | 1 |
| Mikusa, JP | 1 |
| Hernandez, G | 1 |
| Gauvin, D | 1 |
| Wade, C | 1 |
| Zhu, C | 1 |
| Pai, M | 1 |
| Scanio, M | 1 |
| Shi, L | 1 |
| Drizin, I | 1 |
| Gregg, R | 1 |
| Matulenko, M | 1 |
| Hakeem, A | 1 |
| Gross, M | 1 |
| Johnson, M | 1 |
| Marsh, K | 1 |
| Wagoner, PK | 1 |
| Sullivan, JP | 1 |
| Faltynek, CR | 1 |
| Krafte, DS | 1 |
| London, C | 1 |
| Hoyt, SB | 1 |
| Parsons, WH | 2 |
| Williams, BS | 1 |
| Warren, VA | 1 |
| Tschirret-Guth, R | 1 |
| Smith, MM | 2 |
| Priest, BT | 2 |
| McGowan, E | 1 |
| Martin, WJ | 3 |
| Lyons, KA | 2 |
| Li, X | 2 |
| Karanam, BV | 1 |
| Jochnowitz, N | 1 |
| Garcia, ML | 2 |
| Felix, JP | 1 |
| Dean, B | 1 |
| Abbadie, C | 2 |
| Kaczorowski, GJ | 2 |
| Duffy, JL | 1 |
| Bregman, H | 1 |
| Berry, L | 1 |
| Buchanan, JL | 1 |
| Chen, A | 1 |
| Du, B | 1 |
| Feric, E | 1 |
| Hierl, M | 1 |
| Huang, L | 1 |
| Immke, D | 1 |
| Janosky, B | 1 |
| Johnson, D | 1 |
| Ligutti, J | 1 |
| Malmberg, A | 1 |
| Matson, D | 1 |
| McDermott, J | 1 |
| Miu, P | 1 |
| Nguyen, HN | 1 |
| Patel, VF | 1 |
| Waldon, D | 1 |
| Wilenkin, B | 1 |
| Zheng, XM | 1 |
| Zou, A | 1 |
| McDonough, SI | 1 |
| DiMauro, EF | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Bhai, SF | 1 |
| Brown, A | 1 |
| Gajewski, B | 1 |
| Kimminau, KS | 1 |
| Waitman, LR | 1 |
| Pasnoor, M | 1 |
| Barohn, RJ | 2 |
| Fürst, Z | 1 |
| Egashira, N | 1 |
| Hirakawa, S | 1 |
| Kawashiri, T | 1 |
| Yano, T | 1 |
| Ikesue, H | 1 |
| Oishi, R | 1 |
| Statland, JM | 1 |
| Bundy, BN | 1 |
| Wang, Y | 1 |
| Rayan, DR | 1 |
| Trivedi, JR | 1 |
| Sansone, VA | 1 |
| Salajegheh, MK | 1 |
| Venance, SL | 1 |
| Ciafaloni, E | 1 |
| Matthews, E | 1 |
| Meola, G | 1 |
| Herbelin, L | 1 |
| Griggs, RC | 1 |
| Hanna, MG | 1 |
| Asano, K | 1 |
| Sameshima, T | 1 |
| Shirasawa, H | 1 |
| Hisamitsu, T | 1 |
| Attal, N | 1 |
| Rouaud, J | 1 |
| Brasseur, L | 1 |
| Chauvin, M | 1 |
| Bouhassira, D | 1 |
| Shao, PP | 1 |
| Ok, D | 1 |
| Fisher, MH | 1 |
| Li, C | 1 |
| Meinke, PT | 1 |
| Wyvratt, MJ | 1 |
| Ye, F | 1 |
| Lindia, JA | 1 |
| Köhler, MG | 1 |
| Challapalli, V | 2 |
| Tremont-Lukats, IW | 2 |
| McNicol, ED | 2 |
| Lau, J | 2 |
| Carr, DB | 2 |
| Akada, Y | 1 |
| Ogawa, S | 1 |
| Amano, K | 1 |
| Fukudome, Y | 1 |
| Yamasaki, F | 1 |
| Itoh, M | 1 |
| Yamamoto, I | 1 |
| Carroll, I | 1 |
| Tanimoto-Mori, S | 1 |
| Nakazato-Imasato, E | 1 |
| Toide, K | 1 |
| Kita, Y | 1 |
| Hedley, LR | 1 |
| Martin, B | 1 |
| Waterbury, LD | 1 |
| Clarke, DE | 1 |
| Hunter, JC | 2 |
| Kamei, J | 4 |
| Saitoh, A | 1 |
| Kasuya, Y | 3 |
| Hitosugi, H | 2 |
| Colclough, G | 1 |
| Carter, A | 1 |
| Ackerman, WE | 2 |
| Boulton, AJ | 1 |
| Pfeifer, MA | 1 |
| Ross, DR | 1 |
| Schrage, JP | 1 |
| Gelber, DA | 1 |
| Schumer, MP | 1 |
| Crain, GM | 1 |
| Markwell, SJ | 1 |
| Jung, S | 1 |
| Jett, MF | 1 |
| McGuirk, J | 1 |
| Waligora, D | 1 |
| Khandwala, H | 1 |
| Hodge, E | 1 |
| Loomis, CW | 1 |
| Oskarsson, P | 1 |
| Ljunggren, JG | 1 |
| Lins, PE | 1 |
| Duggan, S | 1 |
| Milne, B | 1 |
| Loomis, C | 1 |
| Chapman, V | 1 |
| Ng, J | 1 |
| Dickenson, AH | 1 |
| Kemper, CA | 1 |
| Kent, G | 1 |
| Burton, S | 1 |
| Deresinski, SC | 1 |
| Kieburtz, K | 1 |
| Simpson, D | 1 |
| Yiannoutsos, C | 1 |
| Max, MB | 1 |
| Hall, CD | 1 |
| Ellis, RJ | 1 |
| Marra, CM | 1 |
| McKendall, R | 1 |
| Singer, E | 1 |
| Dal Pan, GJ | 1 |
| Clifford, DB | 1 |
| Tucker, T | 1 |
| Cohen, B | 1 |
| Sakurai, M | 1 |
| Kanazawa, I | 1 |
| Reece, PH | 1 |
| Wyatt, M | 1 |
| O'Flynn, P | 1 |
| Lein, B | 1 |
| Sasaki, M | 1 |
| Zushida, K | 1 |
| Morita, K | 1 |
| Tanaka, S | 1 |
| Laird, JM | 1 |
| Carter, AJ | 1 |
| Grauert, M | 1 |
| Cervero, F | 1 |
| Takasaki, I | 1 |
| Sasaki, A | 1 |
| Andoh, T | 1 |
| Nojima, H | 1 |
| Shiraki, K | 1 |
| Kuraishi, Y | 1 |
| Kawashima, N | 1 |
| Aoki, T | 1 |
| Ohhashi, Y | 1 |
| Stracke, H | 1 |
| Meyer, UE | 1 |
| Schumacher, HE | 1 |
| Federlin, K | 1 |
| Xu, XJ | 1 |
| Hao, JX | 1 |
| Seiger, A | 1 |
| Arnér, S | 1 |
| Lindblom, U | 1 |
| Wiesenfeld-Hallin, Z | 1 |
| Ziegler, D | 1 |
| Gries, FA | 1 |
| Colclough, GW | 1 |
| Juneja, MM | 1 |
| Bellinger, K | 1 |
| Suzuki, K | 1 |
| Toyota, T | 1 |
| Awerbuch, GI | 1 |
| Sandyk, R | 1 |
| Hirotsu, I | 1 |
| Kihara, T | 1 |
| Nakamura, S | 1 |
| Hattori, Y | 1 |
| Hatta, M | 1 |
| Kitakaze, Y | 1 |
| Takahama, K | 1 |
| Hashimoto, Y | 1 |
| Miyata, T | 1 |
| Ishihara, T | 1 |
| Petersen, P | 1 |
| Kastrup, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia[NCT00832000] | Phase 2 | 59 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study[NCT02217267] | Phase 3 | 29 participants (Actual) | Interventional | 2014-08-01 | Completed | ||
| Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)[NCT03254394] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| The Study of Perioperative Intravenous Infusion of Lidocaine on Postoperative Analgesia in Patients Undergoing Single-port Thoracoscopic[NCT04043624] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| High Dose Intravenous Lidocaine vs Hydromorphone for Acute Abdominal Pain in the Emergency Department: A Randomized, Comparative Efficacy Trial[NCT04398316] | Phase 4 | 187 participants (Anticipated) | Interventional | 2021-02-18 | Recruiting | ||
| A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection[NCT00000793] | Phase 2 | 240 participants | Interventional | Completed | |||
| A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy[NCT00000842] | Phase 2 | 270 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time to open the eyes after forced eye closure as measured on a stopwatch. (NCT00832000)
Timeframe: The end of period 1 (week 4) and the end of period 2 (week 9)
| Intervention | Seconds (Mean) |
|---|---|
| Mexiletine | 0.161 |
| Placebo | 0.474 |
The time to open the fist after a forced handgrip as measured on a stopwatch. (NCT00832000)
Timeframe: The end of period 1 (week 4) and the end of period 2 (week 9)
| Intervention | Seconds (Mean) |
|---|---|
| Mexiletine | 0.164 |
| Placebo | 0.494 |
Compound muscle action potential (CMAP) after long periods of exercise as a percentage of baseline. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | percentage of baseline CMAP amplitude (Mean) |
|---|---|
| Mexiletine | 81.8 |
| Placebo | 80.1 |
The maximal post-exercise compound muscle action potential (CMAP) after short periods of exercise as a percent of the baseline measurement. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | percentage of baseline CMAP amplitude (Mean) |
|---|---|
| Mexiletine | 83.1 |
| Placebo | 78.6 |
Measured the amount of myotonia present on needle exam by assigning a number 1-3, with 1 being minimal amount of myotonia on needle stick and 3 being maximal amount of myotonia present on needle stick. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 2.05 |
| Placebo | 2.62 |
Measured the amount of myotonia present on needle exam by assigning a number 1-3, with 1 being minimal amount of myotonia on needle stick and 3 being maximal amount of myotonia present on needle stick. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 2.07 |
| Placebo | 2.54 |
Quality of life scale for patinets with neuromuscular disorders. The INQoL summary score is a weighted average made up of 5 subdomains (activities, social relationships, independence, emotions, and body image) which document the impact of a disease on a patients' quality of life. Scores range from 0-100, and can be interpreted as the percent of maximal detrimental impact on quality of life. A higher score indicates more detrimental impact. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 14.0 |
| Placebo | 16.7 |
Pain measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of pain for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeeks 3-4 of each period
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 1.54 |
| Placebo | 3.17 |
Tiredness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of tiredness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 2.90 |
| Placebo | 3.82 |
Weakness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of weakness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 1.96 |
| Placebo | 3.22 |
Stiffness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of stiffness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine - Period 1 | 2.53 |
| Placebo - Period 1 | 4.21 |
| Mexiletine - Period 2 | 1.60 |
| Placebo - Period 2 | 5.27 |
Maximum voluntary contractions following forced right hand grip were recorded and the time to relax from 90% to 5% of average maximal force was determined using automated analysis software. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | seconds (Mean) |
|---|---|
| Mexiletine | 0.321 |
| Placebo | 0.429 |
The SF-36 is a standard quality of life instrument. The mental composite score represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). The score is nomralized to the population and ranges from 0-100, with the US normal value of 50. A lower score represents a greater impact of quality of life. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine - Period 1 | 47.4 |
| Placebo - Period 1 | 47.7 |
| Mexiletine - Period 2 | 53.1 |
| Placebo - Period 2 | 42.7 |
The SF-36 is a standard quality of life instrument. The physical composite score represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). The score is nomralized to the population and ranges from 0-100, with the US normal value of 50. A lower score represents a greater impact of quality of life. (NCT00832000)
Timeframe: Particiapnts who experienced weakness on mexiletine in either period 1 or period 2.
| Intervention | units on a scale (Mean) |
|---|---|
| Mexiletine | 44.8 |
| Placebo | 39.2 |
The cumulative dose of oxaliplatin received over the course (up to 12 cycles) of mFOLFOX6 treatment regimen. It corresponds to the absolute summed up quantity of Oxaliplatin administered to the patient over time. There is no range for this measure. Since this is a dose-limiting neuropathy prevention study, the higher value can be interpreted as better outcome. (NCT03254394)
Timeframe: 24 weeks
| Intervention | mg (Mean) |
|---|---|
| Placebo + FOLFOX | 1161.8 |
| Lidocaine + FOLFOX | 1294.8 |
"The intensity of cold pain and cold unpleasantness is evaluated separately, assessed daily on a 0-10 scale, upon holding a pre-cooled (~8°C) metal cylinder for 10 seconds. the area under the curve of cold pain and cold unpleasantness vs time is calculated per chemotherapy cycle (every two weeks) and serves as a primary outcome measure.~For intervention (lidocaine+FOLFOX) and control (placebo+FOLFOX) groups, the average of cold pain AUC and cold unpleasantness AUC over 7 cycles was calculated. The average AUCs over 7 cycles were compared between study arms.~The AUC is measured as a score on a 0-10 scale multiplied by 14 days and may range between 0 and 140. Higher AUC values represent more intense cold pain/unpleasantness." (NCT03254394)
Timeframe: 14 weeks
| Intervention | score on a scale*days (Mean) | |
|---|---|---|
| pain AUC | unpleasantness AUC | |
| Lidocaine + FOLFOX | 9.5 | 25.4 |
| Placebo + FOLFOX | 16.4 | 33.1 |
Changes in Neuropathic Pain Symptom Inventory (NPSI) descriptors of neuropathic pain over time from baseline to cycle 3(6 weeks), cycle 6 (12 weeks), and the last follow-up (34-36 weeks). The total NPSI score ranges from 0 to 100; a higher NPSI total score represents a worse neuropathy outcome. The changes in scores from baseline are compared between study arms. (NCT03254394)
Timeframe: 6 weeks, 12 weeks, 34-36 weeks
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| 6 weeks visit | 12 weeks visit | last follow-up visit | |
| Lidocaine + FOLFOX | 0 | 0 | 13.5 |
| Placebo + FOLFOX | 0 | 0 | 3.0 |
"Change in CIPN (Chemotherapy-induced peripheral Neuropathy) score (on EORTC QLQ-CIPN20 tool ) from baseline to the Cycle 6 (12 weeks), and from baseline to last follow-up (34-36 weeks). EORTC QLQ-CIPN20 ranges from 0 (no symptoms) to 100 (worst symptoms). A higher score represents worse neuropathy. The changes in scores are compared between study arms.~EORTC QLQ-CIPN20 tool is a quality of life questionnaire (QLQ) from the European Organization for Research and Treatment of Cancer (EORTC) for evaluation of CIPN." (NCT03254394)
Timeframe: 12 weeks and 34-36 weeks
| Intervention | score on a scale (Median) | |
|---|---|---|
| 12 | 34-36 weeks | |
| Lidocaine + FOLFOX | 4 | 37.0 |
| Placebo + FOLFOX | 2 | 17.0 |
7 reviews available for mexiletine and Pain
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
[Central and peripheral mechanisms in antinociception: current and future perspectives].
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl | 2008 |
Systemic administration of local anesthetic agents to relieve neuropathic pain.
Topics: Administration, Oral; Anesthetics, Intravenous; Anesthetics, Local; Flecainide; Humans; Lidocaine; M | 2005 |
Systemic administration of local anesthetic agents to relieve neuropathic pain.
Topics: Administration, Oral; Anesthetics, Intravenous; Anesthetics, Local; Flecainide; Humans; Lidocaine; M | 2005 |
Systemic administration of local anesthetic agents to relieve neuropathic pain.
Topics: Administration, Oral; Anesthetics, Intravenous; Anesthetics, Local; Flecainide; Humans; Lidocaine; M | 2005 |
Systemic administration of local anesthetic agents to relieve neuropathic pain.
Topics: Administration, Oral; Anesthetics, Intravenous; Anesthetics, Local; Flecainide; Humans; Lidocaine; M | 2005 |
Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Lidocaine; Mexiletine; Pain; Peripheral Nervous System Diseases; Randomi | 2005 |
Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy.
Topics: Anesthetics, Local; Humans; Infusions, Intravenous; Lidocaine; Mexiletine; Pain; Peripheral Nervous | 2007 |
Causes of neuropathic pain.
Topics: Animals; Blood Glucose; Diabetic Neuropathies; Humans; Leg; Lidocaine; Mexiletine; Pain; Regional Bl | 1993 |
Drug treatment of neuropathic pain.
Topics: Aged; Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2000 |
10 trials available for mexiletine and Pain
| Article | Year |
|---|---|
A secondary analysis of PAIN-CONTRoLS: Pain's impact on sleep, fatigue, and activities of daily living.
Topics: Activities of Daily Living; Bayes Theorem; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hy | 2022 |
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cross-Over Studies; Double-Bl | 2012 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy.
Topics: Analgesics; Capsaicin; Diabetic Neuropathies; Exercise Therapy; Female; Glycated Hemoglobin; Humans; | 1993 |
Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group.
Topics: Anti-Arrhythmia Agents; Blood Pressure; Diabetic Neuropathies; Dose-Response Relationship, Drug; Dou | 1997 |
Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial.
Topics: Adult; Analgesics; Cross-Over Studies; Double-Blind Method; HIV Infections; Humans; Mexiletine; Pain | 1998 |
A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.
Topics: Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Anti-Arrhythmia Agents; Double-Blind Method; Dru | 1998 |
Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Lidocaine; Male; Mexiletine; Middle Aged; M | 1999 |
Mexiletine in the treatment of diabetic neuropathy.
Topics: Adult; Aged; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Female; H | 1992 |
Dercum's disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine.
Topics: Adiposis Dolorosa; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Injections, | 1987 |
29 other studies available for mexiletine and Pain
| Article | Year |
|---|---|
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Topics: Action Potentials; Analgesics; Aniline Compounds; Animals; Capsaicin; Evoked Potentials; Furans; Gan | 2007 |
Imidazopyridines: a novel class of hNav1.7 channel blockers.
Topics: Analgesics; Animals; Inflammation; Molecular Structure; NAV1.7 Voltage-Gated Sodium Channel; Pain; P | 2008 |
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
Topics: Acetamides; Administration, Oral; Analgesics; Animals; Binding Sites; Cell Line; ERG1 Potassium Chan | 2011 |
Mexiletine reverses oxaliplatin-induced neuropathic pain in rats.
Topics: Animals; Anti-Arrhythmia Agents; Mexiletine; Organoplatinum Compounds; Oxaliplatin; Pain; Peripheral | 2010 |
Attenuating effect of mexiletine hydrochloride on herpetic pain in mice infected with herpes simplex virus.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; H | 2003 |
Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain.
Topics: Administration, Oral; Amides; Analgesics; Animals; Biphenyl Compounds; Cyclopentanes; Ion Channel Ga | 2005 |
Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats.
Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Gan | 2005 |
Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
Topics: Analgesics; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Formaldehyde; Ganglia, Spina | 2006 |
Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Chronic Disease; Cold Tempe | 2008 |
A comparison of the action of mexiletine and morphine in rodent models of acute and chronic pain.
Topics: Acute Disease; Animals; Chronic Disease; Cold Temperature; Male; Mexiletine; Morphine; Pain; Pain Me | 1995 |
Involvement of delta 1-opioid receptors in the antinociceptive effects of mexiletine in mice.
Topics: Animals; Diabetic Neuropathies; Male; Mexiletine; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antag | 1995 |
Effects of mexiletine on formalin-induced nociceptive responses in mice.
Topics: Animals; Diabetes Mellitus, Experimental; Formaldehyde; Injections, Intraperitoneal; Injections, Spi | 1993 |
Mexiletine for chronic pain.
Topics: Aged; Chronic Disease; Humans; Male; Mexiletine; Pain | 1993 |
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 1997 |
Comparable dose-dependent inhibition of AP-7 sensitive strychnine-induced allodynia and paw pinch-induced nociception by mexiletine in the rat.
Topics: 2-Amino-5-phosphonovalerate; Animals; Dose-Response Relationship, Drug; Foot; Hyperesthesia; Male; M | 1997 |
Use of differential normal pulse voltammetry for the measurement of locus coeruleus catecholaminergic metabolism in an acute anaesthetized rodent model of allodynia: effect of mexiletine.
Topics: Anesthesia; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Catecholamines; Electrodes, Implant | 1997 |
A novel spinal action of mexiletine in spinal somatosensory transmission of nerve injured rats.
Topics: Animals; Anti-Arrhythmia Agents; Behavior, Animal; Evoked Potentials, Somatosensory; Ligation; Male; | 1998 |
Dercum's disease (adiposis dolorosa).
Topics: Adipose Tissue; Adiposis Dolorosa; Anti-Arrhythmia Agents; Female; Humans; Mexiletine; Middle Aged; | 1999 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate.
Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Enzyme Activators; Enzyme Inhibitors; Hyperalgesia; | 2001 |
Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzomorphans | 2001 |
Effects of analgesics on delayed postherpetic pain in mice.
Topics: Acetates; Acute Disease; Acyclovir; Amines; Analgesics; Analgesics, Opioid; Animals; Antiviral Agent | 2002 |
Antinociceptive effect of mexiletine in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Male; Mexiletine; Mice; Mice, Inbred ICR; Nociceptors; Pai | 1992 |
Systemic mexiletine relieves chronic allodynialike symptoms in rats with ischemic spinal cord injury.
Topics: Animals; Female; Injections, Intraperitoneal; Ischemia; Mexiletine; Motor Activity; Pain; Pain Measu | 1992 |
[Treatment of pain in diabetic polyneuropathy].
Topics: Analgesics; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Carbamaze | 1991 |
The management of oral mexiletine and intravenous lidocaine to treat chronic painful symmetrical distal diabetic neuropathy.
Topics: Chronic Disease; Diabetic Neuropathies; Drug Therapy, Combination; Female; Humans; Infusions, Intrav | 1991 |
[Diabetic neuropathy--sensory abnormalities and treatment for painful neuropathy].
Topics: Alprostadil; Anticonvulsants; Antidepressive Agents, Tricyclic; Child; Diabetic Neuropathies; Female | 1991 |
Mexiletine for thalamic pain syndrome.
Topics: Cerebral Hemorrhage; Cerebral Infarction; Female; Humans; Male; Mexiletine; Middle Aged; Multiple Sc | 1990 |
General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Body Temperature; Catalepsy; Cats; Central Ne | 1988 |